NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products

Reuters

2025/08/16

NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products

NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2559450749"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2559450749\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2559450749?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-16 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559450749","market":"nz","top_or_hot":-1,"title":"NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-16 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL7jHYN2:1","article_id":"2559450749","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559450749","pubTimestamp":1755288401,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NAMS":"NEWAMSTERDAM PHARMA CO NV"},"translate_title":"NewAmsterdam Pharma子公司与Menarini签订Obicetrapib产品供应协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":0.9},"content_text":"NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products\n    \n\n        NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}